Moors & Cabot’s Eli Lilly LLY Stock Holding History

Moors & Cabot’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2	Closed	-$3K	–	945
2021 Q4	$3K	Buy	+2	New	+$507	﹤0.01%	884

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moors & Cabot's LLY Position: Q2 2026 in Review

Moors & Cabot reduced its Eli Lilly (LLY) stake by 1.8% in Q2 2026, selling an estimated $419K and leaving 22,840 shares worth $27.4M. The position accounts for 1.07% of the portfolio, ranked #12.

Moors & Cabot first reported a position in LLY in Q1 2014 and has held it in 50 quarters since. 4,634 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Moors & Cabot held 22,840 shares of Eli Lilly worth $27.4M as of Q2 2026.
Moors & Cabot sold 410 Eli Lilly shares in Q2 2026, an estimated $419K.
Eli Lilly made up 1.07% of Moors & Cabot's portfolio in Q2 2026, its #12 holding.
Moors & Cabot first reported a position in Eli Lilly in Q1 2014 and has held it in 50 quarters since.
4,634 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.